News Formal

Cellectis’ stock is the biggest gainer and most active premarket after equity investment, collaboration pact with AstraZeneca

  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 25 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 13%
  • Publisher: 97%

日本 ニュース ニュース

日本 最新ニュース,日本 見出し

Tomi Kilgore is MarketWatch's deputy investing and corporate news editor and is based in New York. You can follow him on Twitter @TomiKilgore.

The U.S.-listed shares of Cellectis S.A.

rocketed 179.3% on very heavy volume in premarket trading Wednesday, after the France-based biotechnology company announced an equity investment of $220 million from AstraZeneca PLC AZN, +0.46% as part of a collaboration agreement that leverages Cellectis’ gene editing technologies. Trading volume ballooned to 10.8 million shares, compared with the full-day average of about 68,000 shares. The stock was the biggest gainer and most active on major U.S. exchanges ahead of the open.

このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む:

 /  🏆 3. in JP
 

コメントありがとうございます。コメントは審査後に公開されます。

日本 最新ニュース, 日本 見出し

Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。

Revvity’s stock tumbles to lead the S&P 500 losers after earnings miss, lowered outlookTomi Kilgore is MarketWatch's deputy investing and corporate news editor and is based in New York. You can follow him on Twitter TomiKilgore.
ソース: MarketWatch - 🏆 3. / 97 続きを読む »